Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Acta Haematol. 2024;147(2):198-218. doi: 10.1159/000533990. Epub 2023 Sep 6.
In the past decade, there have been significant breakthroughs in immunotherapies for B-cell lymphoid malignancies and multiple myeloma, but progress has been much less for acute myeloid leukemia (AML). Nevertheless, challenge begets innovation and several therapeutic strategies are under investigation.
In this review, we review the state of the art in AML immunotherapy including CD33- and CD123-targeted agents, immune checkpoint inhibition, and adoptive cell therapy strategies. We also share conceptual frameworks for approaching the growing catalog of investigational AML immunotherapies and propose future directions for the field.
Immunotherapies for AML face significant challenges but novel strategies are in development.
在过去的十年中，B 细胞淋巴肿瘤和多发性骨髓瘤的免疫疗法取得了重大突破，但急性髓细胞白血病（AML）的进展要小得多。然而，挑战带来了创新，目前正在研究多种治疗策略。
在这篇综述中，我们回顾了 AML 免疫治疗的最新进展，包括针对 CD33 和 CD123 的靶向药物、免疫检查点抑制以及过继细胞治疗策略。我们还分享了处理日益增多的 AML 免疫治疗研究目录的概念框架，并为该领域提出了未来的方向。
AML 的免疫疗法面临重大挑战，但新的策略正在开发中。
